AEG 40826

Drug Profile

AEG 40826

Alternative Names: AEG40826; HGS-1029

Latest Information Update: 20 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aegera Therapeutics
  • Developer Human Genome Sciences; Pharmascience
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Inhibitor of apoptosis protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Solid tumours
  • Discontinued Lymphoma

Most Recent Events

  • 20 May 2016 No recent reports on development identified- Phase-I for Solid tumours in Canada (IV)
  • 12 Dec 2012 Pharmascience intends to initiate a phase Ib trial of AEG 40826 in the near future
  • 12 Dec 2012 Pharmascience Inc. regains global rights to AEG 4086 as part of an agreed-upon termination of its oncology collaboration with Human Genome Sciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top